Hematopoietic Stem Cell Transplantation Market to be driven by biotechnology firms are expected to grow at a CAGR of 11.90% during the forecast period 2024 to 2032.

Market Research Future (MRFR) has published a cooked research report on the “Hematopoietic Stem Cell Transplantation Market” that contains information from 2019 to 2032. The Hematopoietic Stem Cell Transplantation Market is estimated to register a CAGR of 11.90% during the forecast period of 2024 to 2032.

MRFR recognizes the following companies as the key players in the global Hematopoietic Stem Cell Transplantation Market— Pluristem Therapeutics Inc., CellGenix GmbH, Regen Biopharma Inc., Lonza Group, Sanofi, Taiga Biotechnologies, Inc., Takeda Pharmaceutical Company Limited, Escape Therapeutics, Inc., Bluebird Bio, Talaris Therapeutics

Market Highlights

The global Hematopoietic Stem Cell Transplantation Market is expected to register a CAGR of 11.90% during the forecast period and is estimated to reach USD 7.7 billion by 2032.

The rising occurrence of leukemia and lymphoproliferative disorders, coupled with heightened research and development efforts by biotechnology firms, are the primary factors propelling market growth.

Segment Analysis

The global Hematopoietic Stem Cell Transplantation (HSCT) Market has been segmented based on the Transplant Type, Indication, and Application.

Based on Transplant Type, the market is segmented into Allogeneic and Autologous. The Autologous segment was attributed to holding the largest market share in 2023. Autologous transplantation eliminates the necessity of seeking a compatible donor, a task often arduous in allogeneic transplantation. This minimizes the duration and resources expended in donor search, thereby expediting the transplantation process. Additionally, autologous HSCT permits the administration of elevated doses of chemotherapy or radiation, potentially enhancing the eradication of cancer cells or immunosuppression in autoimmune disorders. The subsequent infusion of the patient's stem cells aids in the restoration of both bone marrow and the immune system.

Based on the Indication, the Hematopoietic Stem Cell Transplantation Market has been segmented into Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, Other Non-Malignant Disorders. The Acute Myeloid Leukemia (AML) segment was expected to hold the largest market share in 2023. Despite improvements in treatment, AML continues to pose a significant global health challenge. The incidence of AML is on the rise, especially among older individuals. In 2023, the National Cancer Institute reported a rate of 4.1 new cases of acute myeloid leukemia per 100,000 men and women annually, with a death rate of 2.7 per 100,000. With the increasing number of AML cases, there is a growing demand for treatment options, including HSCT.

Based on the Application, the Hematopoietic Stem Cell Transplantation Market has been segmented into Bone Marrow Transplant, Peripheral Blood Stem Cells Transplant, and Cord Blood Transplant. The Bone Marrow Transplant segment was expected to hold the largest market share in 2023. A bone marrow transplant, also known as a stem cell transplant, involves the infusion of healthy blood-forming stem cells into the body to replace malfunctioning or depleted bone marrow. This procedure is utilized to address conditions such as leukemia, myeloma, lymphoma, and other disorders affecting the blood and immune system. The growth of this segment is expected to be driven by increased research and development activities during the forecast period. For instance, Gamida Cell Ltd. announced in October 2020 the successful completion of the Phase 3 study of omidubicel, an innovative advanced cell therapy aimed at providing a potentially life-saving treatment option for patients requiring a bone marrow transplant. The study met all three of its secondary endpoints, indicating promising advancements in this therapeutic area.

Explore In-depth Market Details [Table of Content, List of Figures, List of Tables] of Hematopoietic Stem Cell Transplantation Market Research Report

Regional Analysis

The global Hematopoietic Stem Cell Transplantation Market, based on region, has been divided into North America, Europe, Asia-Pacific, and the Rest of the World. North America consists of the US and Canada. The Europe Hematopoietic Stem Cell Transplantation Market comprises Germany, France, the UK, Italy, Spain, and the rest of Europe. The Hematopoietic Stem Cell Transplantation Market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World's Hematopoietic Stem Cell Transplantation Market comprises the Middle East, Africa, and Latin America.

The largest market share for the Hematopoietic Stem Cell Transplantation Market was maintained by the North American regional sector. North America is anticipated to maintain dominance in the overall hematopoietic stem cell transplantation market. This is attributed to factors such as the increasing incidence of leukemia and growing investments in research and development by both public and private sectors in the region. For example, according to data released by the Canadian Cancer Society in May 2022, it is projected that 6,700 Canadians will be diagnosed with leukemia in 2022. Among them, approximately 4,000 men and 2,700 women are expected to receive diagnoses, with 1,300 deaths anticipated due to the disease. Stem cell transplants play a crucial role in leukemia treatment by facilitating the replacement of damaged blood cells with healthy ones. Hematopoietic stem cells, capable of differentiating into various cell types, aid in this process. Consequently, the rising leukemia cases are projected to drive the demand for hematopoietic stem cell transplantation, thereby fueling market growth in the coming years.

Moreover, the Europe market has been persistently growing over the forecast period. The dominance of the region is attributed to a general improvement in transplant success rates, straightforward technical procedures, and the high affluence of the population. In 2017, more than 30,000 patients across the European Union (EU) underwent hematopoietic stem cell transplantation to replace their own damaged blood-forming cells with healthy ones. The largest numbers of stem cell transplants were recorded in Germany (7,700), France (5,500), Italy (5,100), the United Kingdom (3,800), and Spain (3,100).

The APAC hematopoietic stem cell transplantation market is anticipated to grow the fastest during the forecast period, primarily driven by the growth of medical tourism. India has emerged as a significant hub for medical tourism, offering high-quality healthcare services at competitive prices and state-of-the-art medical facilities. Additionally, India has gained prominence as a preferred destination for yoga and wellness, emphasizing traditional therapies through AYUSH. The influx of international patients to India has surged from 430,000 in 2016 to 700,000 in 2019, contributing to an estimated market size ranging between USD 5-6 billion in 2019. To capitalize on the industry's potential, the government is actively working to position India as the top destination for medical tourism globally, aiming to triple its revenue to $13 billion within four years. This endeavor is supported by a significant increase in government spending on health and well-being, with a proposed outlay of US$ 28.7 billion, marking a 137% rise from the previous year's budget allocation. India's attractiveness as a destination for stem cell transplants is further bolstered by the availability of cutting-edge facilities, skilled medical professionals, and advanced technology. These factors attract medical tourists who may face challenges accessing or affording similar treatments in their home countries.

Furthermore, the rest of the world's Hematopoietic Stem Cell Transplantation Market is divided into the Middle East, Africa, and Latin America. The prevalence of blood disorders such as leukemia, lymphoma, and certain genetic diseases is on the rise in the Middle East, Africa, and Latin America. Between June 2021 and May 2022, a total of 41 patients were registered, including 18 with acute myeloid leukemia (AML), 3 with acute promyelocytic leukemia (APL), and 1 with blastic plasmacytoid dendritic cell neoplasm (BPDCN). Furthermore, there's an increasing incidence of cancers like multiple myeloma in these regions. As a result, hematopoietic stem cell transplantation (HSCT) is becoming a preferred treatment option for these conditions, leading to a higher demand for transplantation services.

Key Findings of the Study

• The global Hematopoietic Stem Cell Transplantation Market is expected to reach USD 7.7 billion by 2032, at a CAGR of 11.90% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market due to rising leukemia incidences and increased investment in research and development by the public and commercial sectors.


• Based on Transplant Type, the Autologous segment was attributed to holding the largest market in 2023, with an approximate market share of 55–60%.


• Pluristem Therapeutics Inc., CellGenix GmbH, Regen Biopharma Inc., Lonza Group, Sanofi, Taiga, Biotechnologies, Inc., Takeda Pharmaceutical Company Limited, Escape Therapeutics, Inc., Bluebird Bio, and Talaris Therapeutics are the key market players.